Abstract
Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.
Original language | English |
---|---|
Journal | Cancer Treatment Reviews |
Volume | 36 |
Issue number | SUPPL. 3 |
DOIs | |
Publication status | Published - Nov 2010 |
Keywords
- Adjuvant
- Bevacizumab
- Capecitabine
- Cetuximab
- Colorectal carcinoma
- Irinotecan
- Metastatic
- Neoadjuvant
- Oxaliplatin
- Radiotherapy
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging